Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
The objective of this trial is to evaluate R327’s potential as a topical broad-spectrum anti-infective treatment.
- The objective of this trial is to evaluate R327’s potential as a topical broad-spectrum anti-infective treatment.
- In the coming months, additional study sites both locally and overseas will become active and include the broader patient population in the study.
- Of the estimated 537 million people worldwide who have diabetes, 19–34% will develop a DFU in their lifetime.
- “A non-invasive method to treat the burdensome challenges of diabetic foot ulcer infections gives hope to better patient outcomes and avoid limb amputation, as is so commonly the case with these complicated patients.